Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
Alimentary Pharmacology & Therapeutics2016Vol. 44(11-12), pp. 1199–1212
Citations Over TimeTop 1% of 2016 papers
Andreas Stallmach, C. Langbein, Raja Atreya, Tony Bruns, Axel Dignaß, K Ende, Jochen Hampe, Franz Hartmann, Markus F. Neurath, Jochen Maul, J. Preiß, Renate Schmelz, Britta Siegmund, H Schulze, Niels Teich, Ulrike von Arnim, Daniel C. Baumgart, Carsten Schmidt
Abstract
Among patients who started vedolizumab for active inflammatory bowel disease, clinical remission rates are 21-25% after 54 weeks.
Related Papers
- → Calprotectin instability may lead to undertreatment in children with IBD(2019)35 cited
- → Vedolizumab for the treatment of ulcerative colitis(2015)2 cited
- → Vedolizumab for induction and maintenance of remission in Crohn’s disease(2020)1 cited
- → Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease – authors’ reply(2016)
- → PWE-056 Single centre experience of vedolizumab in the management of moderate to severe ulcerative colitis and crohn’s disease(2017)